table of contents
Poulpharm, InnoSer and C-Path strategic partnership
Poulpharm and InnoSer, Connected-Pathology Forge Strategic Partnership to Expand Preclinical and Histopathology Services.
We are pleased to announce a strategic partnership between Poulpharm, a CRO with expertise in microbiology and preclinical veterinary research; InnoSer, a preclinical contract research organization (CRO); and Connected-Pathology, a CRO specialized in advanced digital histopathology, join forces to deliver integrated preclinical services tailored for both veterinary and human healthcare research.
Together, the partners aim to enable seamless access to integrated multi-species expertise, focusing on advanced preclinical drug development and automated histopathology services, streamlining preclinical research for both human and veterinary drug development.
This strategic partnership is designed to enhance the preclinical capabilities of each partner, including advanced drug development and histopathology services. By aligning their complementary strengths, InnoSer and Poulpharm, through Connected-Pathology, will provide seamless preclinical support by integrating multi-species expertise, advanced digital histopathology, and streamlined workflows, accelerating research timelines.
This strategic collaboration combines:
- Connected-Pathology’s advanced histopathology and digital pathology services, expanding its scope into multi-species and translational studies
- InnoSer’s translational research platforms and preclinical drug development capabilities
- Poulpharm’s applied expertise in preclinical multi-species research and diagnostic services
By working strategically together, the three partners aim to:
- Provide seamless access to larger animal models and multi-species expertise, enabling faster, more informed and translational drug development
- Deliver high-throughput histopathology services including IHC, IF, ISH, and AI-supported image and biomarker analysis across multiple study types
- Provide end-to-end study support, from in vivo research to digital pathology and regulatory reporting
“This partnership reflects our shared vision to deliver smarter, more connected research services,” said Maarten De Gussem, DVM, Manager and Veterinarian at Poulpharm. “Together, we are building a stronger, innovation-driven foundation for translational research.”
“This partnership allows Connected-Pathology to extend its advanced digital histopathology solutions into broader preclinical applications across multiple species and diverse study types, significantly enhancing the depth and flexibility of our service offerings, said Wim Tiest, Manager at Connected-Pathology.”
Kris Motmans, PhD, CEO of InnoSer, further adds, “The combined strengths of Poulpharm’s multi-species preclinical capabilities, InnoSer’s advanced drug development platform, and Connected-Pathology’s state-of-the-art histopathology services empower us to deliver seamless, integrated research solutions that accelerate drug development pipelines.”
The collaboration ensures clients benefit from faster timelines, deeper insights, and seamlessly connected pathology and laboratory workflows — supporting the next generation of preclinical drug development.
